From: M2e-based universal influenza vaccines: a historical overview and new approaches to development
Major feature | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | Reference |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The most conservative part of M2e | S | L | L | T | E | V | E | T | P | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
TCN-031 and TCN-032 antibodies recognition site | S | L | L | T | E | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | [37] |
O19 antibody recognition site | S | L | L | T | E | V | E | T | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | [32] |
L18 antibody recognition site | Â | Â | L | T | E | V | E | T | P | I | R | N | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
S1 antibody recognition site | Â | Â | Â | Â | Â | V | E | T | P | I | R | N | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
Influenza A and B virus neutralizing activity in vitro | S | L | L | T | E | V | E | T | P | I | R | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | [77] |
Presence of B-cell epitope and 14C2 antibody recognition site | Â | Â | Â | Â | E | V | E | T | P | I | R | N | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | [78] |
High affinity of binding with HLA-A2; presence of T-cell epitope | Â | L | L | T | E | V | E | T | P | I | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | [36] |
Potential epitope | Â | Â | Â | Â | Â | Â | E | T | P | I | R | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | [94] |
Presence of CTL-cell epitopes | S | L | L | T | E | V | E | T | P | I | R | N | E | W | G | Â | Â | Â | Â | Â | Â | Â | Â | |
Some critical residues for T-helpers | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | C | R | C | N | D | S | S | D | |
Recognition of HLA-B44-restricted CD8+ CTL line 124 | Â | Â | Â | Â | Â | V | E | T | P | I | R | N | E | W | Â | Â | Â | Â | Â | Â | Â | Â | Â | [52] |
MHC class II H-2d-restricted epitope | Â | Â | Â | Â | Â | Â | E | T | P | I | R | N | E | W | G | S | R | Â | Â | Â | Â | Â | Â | [26] |
L66 antibody recognition site | S | L | L | T | E | V | E | T | P | I | R | N | E | W | G | Â | Â | Â | Â | Â | Â | Â | Â | [128] |
N547 antibody recognition site | Â | L | L | T | E | V | E | T | P | I | R | N | E | W | G | Â | Â | Â | Â | Â | Â | Â | Â | |
Z3G1 antibody recognition site | Â | L | L | T | E | V | E | T | P | I | R | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
C40G1 antibody recognition site | Â | Â | Â | Â | Â | Â | Â | T | P | I | R | N | E | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | |
14C2 antibody recognition site | Â | Â | Â | Â | E | V | E | T | P | I | R | N | E | W | Â | Â | Â | Â | Â | Â | Â | Â | Â |